Engitix leverages one of the largest proprietary datasets of high-resolution extracellular matrix (ECM) profiles across cancer and fibrotic diseases to discover and develop new drugs. By decoding disease-specific ECM signatures, the company designs therapeutics intended to act directly within diseased tissue microenvironments. Its preclinical pipeline includes multiple oncology and fibrosis programs that it plans to progress toward the clinic using the newly secured capital. Engitix’s strategy sits at the intersection of data science, biology and drug development, aiming to deliver differentiated ECM-targeted medicines that improve patient outcomes. Current external relationships include a drug-discovery partnership with Dompé farmaceutici and development collaborations with Takeda focused on advanced fibrotic liver diseases. The firm states that the additional funds will accelerate its platform expansion and pipeline advancement. No revenue or user metrics were disclosed in the article.

Total raised

$85M

Funding rounds

3

Latest round

Series A

Latest activity

Jan 2026